OptimizeRx Stock Plunges 7% In Monday Trading, Erasing $10 Million In Market Value
The healthcare marketing company's shares had fallen 13% over the previous month, and it lowered annual sales expectations Wednesday.
OptimizeRx, which helps pharmaceutical companies market to healthcare providers and patients, plunged 7.4% to $6.80 in Monday trading, as of 12:50 PM ET, erasing $10 million in market value. The stock was on pace for its third decline of 7% or more this month.
A Slide Far Beyond The Market
The catalyst for Monday's decline was not immediately clear. At that reading, OptimizeRx was 58% below its 52-week high, with a total market value of about $128 million.
OptimizeRx shares were down 40% year to date at Friday's close, while the S&P 500 had gained 11%. The shares had lost 13% over the previous month before Monday's session.
Lower Sales Expectations, Concentrated Customers
OptimizeRx lowered its annual sales expectations Wednesday. It repeated the outlook in an SEC filing Friday, putting its revenue forecast at $87 million–$93 million.
The company sells pharmaceutical brands and their agencies tools for choosing audiences, planning campaigns and delivering advertising. Its technology uses AI to find relevant audiences, with messages reaching them through electronic health records, prescribing software and consumer media.
OptimizeRx also supplies prescription copay details and alerts about pharmacies able to fill prescriptions. Its network reaches more than two million U.S. healthcare providers and millions of patients.
The customer base includes more than 100 pharmaceutical manufacturers. Revenue was concentrated among its biggest accounts: the top five customers generated approximately 47% of revenue in 2025.
Management is scheduled to participate Wednesday in the 15th Annual ROTH Technology Conference in New York.
Sources
- OptimizeRx to Participate in the 15th Annual ROTH — globenewswire.com
- The company's filing (OptimizeRx) — SEC filing
- OptimizeRx — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR